| Molecular Formula | C20H31N3O2S2 |
| Molar Mass | 409.61 |
| Density | 1.162 |
| Melting Point | 126-127 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6)) |
| Boling Point | 535.0±43.0 °C(Predicted) |
| Solubility | Soluble in DMSO (82 mg/ml), water (< 1 mg/ml), and ethanol (60 mg/ml). |
| Appearance | White solid |
| Color | White to Off-White |
| pKa | 6.03±0.40(Predicted) |
| Storage Condition | +2C to +8C |
| MDL | MFCD18384970 |
| Use | A pleckstrin homology domain inhibitor to Akt and PKB Kinase (PDPK1). |
| In vitro study | PH-427 is a platelet leukocyte C kinase substrate homology (PH) domain inhibitor of Akt/pdpk1. 10 M PH-427 acts on PC-3 prostate cancer cells, significantly reduced by p-Ser241-PDPK1 and p-Thr308-Akt, indicating that PHT-427 can inhibit Akt and pdkp1. PHT-427 acts on the plasma membrane and also inhibits Akt and PDKP1 PH domain translocation. PHT-427 induces apoptosis and inhibits AKT phosphorylation (mainly at Ser473 residue and less at Thr308 residue, IC50 is 6.3 μm, which does not affect all AKT protein expression. PHT-427 acts on Panc-1 cells and has an antiproliferative effect with an IC50 of 65 μm. |
| In vivo study | PHT-427 acts on BxPC-3 pancreatic cancer, MCF-7 breast cancer and A- 549 NSCL cancer xenografts, with significant anti-tumor activity. PHT-427 at a dose of 125 to 250 mg/kg on BxPC-3, tumor growth was inhibited by 80%. |